December 28, 2017, Yinfeng Bioengineering Group Co., Ltd. and Angiocrine Bioscience, Inc.(San Diego, CA) reached consensus on E-CEL technology patent licensing, technology sharing, shareholding cooperation, and joint ventures in China, signing a Letter of intent for clinical application and joint research of development of cord blood hematopoietic stem cell expansion technology in vitro (E-CEL). Yinfeng Bio Group will obtain the exclusive license to use patents, core technologies and test data necessary for the clinical development and commercialization of AB-110 (derived from E-CEL technology) in China.

Angiocrine has an in-house developed endothelial cell core technology for in vitro proliferating human umbilical cord blood-derived CD34+ hematopoietic stem cells (E-CEL technology, which allows it to expanded functional hematopoietic stem and precursor cells to be more than 100 times greater. The expanded functional hematopoietic stem cells and precursor cells are mainly used for the treatment of leukemia, malignant lymphoma, aplastic anemia, multiple myeloma and other hematological malignancies. They are the world's leading innovative umbilical cord blood stem cell therapeutic products. Non-clinical evaluations have verified the safety and efficacy of E-CEL technology in murine and non-human primate models. Currently, Angiolocine has obtained the US FDA clinical trial approval document and will conduct a multi-center trial in the United States in June 2018 called AB-110 (expanded CD34+ hematopoietic stem cells and precursor cells were co-cultured with E-CEL) phase I b clinical trials.

Yinfeng Biotechnology Group will cooperate with Angiocrine to carry out AB-110 clinical research in China in parallel with United States. After confirming its safety and efficacy, Chinese patients with hematological diseases can have the privilege over the rest of the world to benefit from AB-110 clinical research.

About Angiocrine

Angiocrine Bioscience is a biopharmaceutical company based in San Diego, California, USA, and a world leader in regenerative engineering endothelial cell research. Angiocrine's proprietary E-CELTM technology can genetically modifies vascular endothelial cells (hUVECs) by inserting the E4ORF1 gene. The modified hUVECs maintain the cells' original function and allow them to replicate. The EPC cell line that creates immortality is still in a state of transformation (that means, it is either immortal or tumorigenic) and can be used as a culture platform for large-scale expansion of stem cells and precursor somatic cells in vitro with stem umbilical cord blood, and regeneration and repair process can be initiated in the damaged blood system after transplantation.